Your browser doesn't support javascript.
loading
Lung function trajectories in patients with idiopathic pulmonary fibrosis.
Neely, Megan L; Hellkamp, Anne S; Bender, Shaun; Todd, Jamie L; Liesching, Timothy; Luckhardt, Tracy R; Oldham, Justin M; Raj, Rishi; White, Eric S; Palmer, Scott M.
Affiliation
  • Neely ML; Duke Clinical Research Institute, Durham, NC, USA. megan.neely@duke.edu.
  • Hellkamp AS; Duke University Medical Center, Durham, NC, USA. megan.neely@duke.edu.
  • Bender S; Duke Clinical Research Institute, Durham, NC, USA.
  • Todd JL; Duke University Medical Center, Durham, NC, USA.
  • Liesching T; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
  • Luckhardt TR; Duke Clinical Research Institute, Durham, NC, USA.
  • Oldham JM; Duke University Medical Center, Durham, NC, USA.
  • Raj R; Lahey Hospital & Medical Center, Burlington, MA, USA.
  • White ES; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Palmer SM; Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
Respir Res ; 24(1): 209, 2023 Aug 24.
Article in En | MEDLINE | ID: mdl-37612608
ABSTRACT

BACKGROUND:

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease characterised by decline in lung function. We evaluated trajectories of forced vital capacity (FVC) and diffusing capacity (DLco) in a cohort of patients with IPF.

METHODS:

Patients with IPF that was diagnosed or confirmed at the enrolling centre in the previous 6 months were enrolled into the IPF-PRO Registry between June 2014 and October 2018. Patients were followed prospectively, with lung function data collected as part of routine clinical care. Mean trajectories of FVC and DLco % predicted in all patients and in subgroups by characteristics assessed at enrolment were estimated using a joint model that accounted for factors such as disease severity and visit patterns.

RESULTS:

Of 1002 patients in the registry, 941 had ≥ 1 FVC and/or DLco measurement after enrolment. The median (Q1, Q3) follow-up period was 35.1 (18.9, 47.2) months. Overall, mean estimated declines in FVC and DLco % predicted were 2.8% and 2.9% per year, respectively. There was no evidence that the mean trajectories of FVC or DLco had a non-linear relationship with time at the population level. Patients who were male, white, had a family history of ILD, were using oxygen, or had prior/current use of antifibrotic therapy at enrolment had greater rates of decline in FVC % predicted. Patients who were male or white had greater rates of decline in DLco % predicted.

CONCLUSIONS:

Data from the IPF-PRO Registry suggest a constant rate of decline in lung function over a prolonged period, supporting the inexorably progressive nature of IPF. A graphical abstract summarising the data in this manuscript is available at https//www.usscicomms.com/respiratory/IPF-PRORegistry_LungFunctionTrajectories . TRIAL REGISTRATION NCT01915511.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Idiopathic Pulmonary Fibrosis Type of study: Diagnostic_studies / Prognostic_studies Limits: Female / Humans / Male Language: En Journal: Respir Res Year: 2023 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Idiopathic Pulmonary Fibrosis Type of study: Diagnostic_studies / Prognostic_studies Limits: Female / Humans / Male Language: En Journal: Respir Res Year: 2023 Type: Article Affiliation country: United States